Technology areas: Biotechnology & Pharmaceuticals • Communications
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Humanscape Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, which indicates that the company's research and development efforts are being evaluated under different technical standards at the patent office. This distribution requires a broader prosecution strategy than a single-unit portfolio, as the legal team must address the specific precedents and examination guidelines of two separate divisions. The presence of 2 distinct art units suggests that the company is pursuing intellectual property across different sub-sectors of the biotechnology field.
The portfolio involves 2 distinct examiners, with LANDSMAN, ROBERT S identified as the busiest examiner. This examiner is responsible for 1 busiest examiner pending office action. Since the 2 pending office actions are split between different examiners, the company must navigate multiple individual examination styles simultaneously. This diversity in the prosecution profile means that the success of the portfolio is not tied to a single individual, providing some level of variety in the feedback received from the patent office. For a practitioner, managing this portfolio involves coordinating responses that satisfy the requirements of multiple examiners while maintaining a cohesive strategy for the company's pharmaceutical innovations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
| SHUI, MING | 1 | 58.4% | +49.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552133 | COMPOSITION FOR DIFFERENTIAL DIAGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | LANDSMAN, ROBERT S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552133 | COMPOSITION FOR DIFFERENTIAL DIAGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | LANDSMAN, ROBERT S | — |
| 18462584 | SYSTEM FOR GENERATING AND EDITING ULTRASOUND IMAGES | SHUI, MING | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 2663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18552133 | COMPOSITION FOR DIFFERENTIAL DIAGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | LANDSMAN, ROBERT S | 1681 | §101§103§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18462584 | SYSTEM FOR GENERATING AND EDITING ULTRASOUND IMAGES | SHUI, MING | 2663 | §112 | Final Rejection | — | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHumanscape Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert S Landsman has the most, with 1 of Humanscape Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
